Sex Differences in Pulmonary Hypertension and Associated Right Ventricular Dysfunction

INTRODUCTION

Pulmonary hypertension (PH) is a heterogenous disease associated with poor clinical outcomes (1). Clinically, PH can be classified by World Health Organization groups based on etiology. PH is also often grouped by hemodynamic assessment into precapillary PH, postcapillary PH, and mixed PH, which carry significant prognostic and therapeutic implications, particularly for PH with a precapillary component (1). In addition, one of the strongest predictors of mortality in this patient population is RV dysfunction, a frequent long-term consequence of PH and associated with poor prognosis (2).

Sex differences have long been observed in pulmonary arterial hypertension (PAH), a subset of PH also known as WHO Group 1 PH with precapillary hemodynamic characteristics. Specifically, PAH is noted to have a much higher prevalence in women compared with men, and yet men appear to have worse RV dysfunction and worse survival, suggesting sex-specific phenotypes with regards to associated RV dysfunction (3). The etiology of these differences remains unclear, but some have postulated that sex hormones such as higher levels of estrogen may be responsible for both the increased risk women face in developing PAH as well as their improved RV function and survival compared with men (3).

Despite the extensive study of sex differences in prevalence and clinical trajectory of PAH, little is still known about sex differences across other hemodynamic PH subtypes. In this context, we sought to study sex differences in PH prevalence, associated RV dysfunction, and clinical outcomes across a broad and clinically heterogeneous hospital-based sample of individuals undergoing right heart catheterization (RHC). Based on what is known about PAH, we hypothesized greater prevalence in women compared with men in precapillary but not postcapillary PH, as well as better RV function and clinical outcomes in women compared with men across all hemodynamic PH subtypes.

METHODS

RESULTS

Sex differences in prevalence of PH and hemodynamic subtypes

Among 8285 individuals who underwent right heart catheterization between 2005-2016, 5208 (63%) met criteria for PH, as defined by a mean pulmonary arterial pressure (mPAP) >20 mmHg. There was no significant sex difference in the prevalence of overall PH, with n= 2032 (62%) women and n=3176 (63%) men meeting PH criteria (p=0.96, baseline characteristics in Supplemental Table 1).

View this table:

• View inline
• View popup
• Download powerpoint

Supplemental Table 1. Baseline characteristics by sex in overall population, (n= 8285)

Among individuals with PH, average age was 64±12 years and 39% were women. Men were significantly more likely to have comorbid conditions including previous MI, previous HF, hypertension, diabetes mellitus, hypercholesteremia, and OSA (p <0.001 for all). However, women were more likely to have chronic lung disease compared with men (20.2% vs 16.7%, p=0.001). The remaining baseline characteristics of individuals with PH are shown in Table 1.

View this table:

• View inline
• View popup
• Download powerpoint

Table 1. Clinical characteristics of men and women with PH, n= 5208

We found that hemodynamic PH subtypes differed significantly by sex (Figure 1). Overall, women were more likely to have pre-capillary PH and men were more likely to have post-capillary PH. Specifically, 26% of women vs 19% of men had pre-capillary (P<0.001), 34% vs 44% had post-capillary (P 0.03), and 26% vs 23% had mixed PH (P=0.08).

• Download figure
• Open in new tab

Figure 1. Hemodynamic PH subtypes among women and men with PH

Prevalence of hemodynamic PH subtypes in women and men. Among women with PH, 31% (n = 544) had precapillary PH, 39% had post-capillary PH (n = 685), and 30% had mixed (n = 527). Among women with PH, 22% (n = 605) had precapillary PH, 51% had post-capillary PH (n = 1402), and 27% had mixed (n = 743). Note that total individuals with precapillary, postcapillary, and mixed PH in our study was 4506 out of 5208 total individuals with PH; the remaining 702 individuals with PH who did not meet criteria for one of these hemodynamic PH subtypes were excluded in this figure.

Sex differences in RV function among individuals with PH

Among individuals with PH, female sex was associated with better RV function as ascertained using hemodynamic indices (Table 2). Specifically, women with PH had higher PAPi (β 0.18, SE −0.03, p <0.001), lower RA:PCWP ratio (β −0.18, SE −0.03, p <0.001), and higher RVSWI (β 0.17, SE −0.03, p <0.001) in multivariable adjusted analyses.

View this table:

• View inline
• View popup
• Download powerpoint

Table 2. Association of female sex with indices of RV Function in individuals with PH.

When stratified across PH hemodynamic subtypes, these sex differences in RV function persisted for PAPi and RA:PCWP but not for RVSWi (Table 2). Women had higher PAPi compared with men in pre-capillary PH (β 0.13, SE 0.03, p <0.001), post-capillary PH (β 0.1, SE 0.03, p <0.001), and mixed PH (β 0.12, SE 0.03, p <0.001) (Supplemental figure 1). Women also had lower RA:PCWP ratio in pre-capillary PH (β −0.17, SE 0.03, p <0.001), post-capillary PH (β −0.18, SE 0.03, p <0.001), and mixed PH (β −0.15, SE 0.03, p <0.001).

• Download figure
• Open in new tab

Supplemental figure 1. Sex differences in RV function by hemodynamic indices between women and men with PH.

Violin plots demonstrating differences in RV function by hemodynamic indices (PAPi, RA:PCWP ratio, and RVSWI) stratified by men (blue) and women (red) for all individuals with PH. Variables were natural log-transformed. Women with PH had better RV function compared with men by all three indices, with higher PAPi (β 0.18, SE −0.03, p <0.001), lower RA:PCWP ratio (β −0.20, SE −0.03, p <0.001), and higher RVSWI (β 0.17, SE −0.03, p <0.001).

Sex differences in clinical outcomes for PH

We next examined the association of sex with clinical outcomes among individuals with PH. Over a median follow-up time of 7.3 years (IQR 4.2 – 10 years), 4023 individuals experienced HF hospitalizations (1625 among women, 2398 in men), with 3549 all-cause death events (1413 in women, 2136 in men).

In multivariable-adjusted analyses, we found that female sex was associated with 17% lower hazard of heart failure hospitalization (HR 0.83, 95% CI 0.74– 0.91, p <0.001). This was driven predominantly by individuals with postcapillary PH, where women with postcapillary PH were significantly less likely to experience HF hospitalization than men (HR 0.79, 95% CI 0.68-0.93, p-value = 0.007, Table 3), whereas no differences in HF hospitalization were observed among those with pre-capillary or mixed PH. Further, we observed no sex differences in risk of mortality among PH overall (HR 0.92, 95% CI 0.84-1.00, p = 0.05, Figure 2), nor by PH subtype.

• Download figure
• Open in new tab

Figure 2. Association of female sex with adverse outcomes among individuals with PH

A forest plot demonstrating age-adjusted and multivariable analyses with confidence intervals for the association between sex and adverse outcomes, specifically heart failure hospitalization and mortality. Multivariable models were adjusted for age, sex, hypertension, diabetes mellitus, obstructive sleep apnea, chronic lung disease, prevalent myocardial infarction, prevalent heart failure.

View this table:

• View inline
• View popup
• Download powerpoint

Table 3. Association of female sex with clinical outcomes in individuals with PH

DISCUSSION

We examined sex differences in prevalence of PH, hemodynamic PH subtypes, and associated RV dysfunction and clinical outcomes in a large hospital-based sample representing a broad spectrum of cardiopulmonary disease referred for RHC. While prevalence of overall PH was similar among women and men, women were more likely to have precapillary PH while men were more likely to have postcapillary PH. Among individuals with PH, female sex was consistently associated with better hemodynamic indices of RV function and lower risk of heart failure hospitalization. These findings build on a current body of literature that has thus far primarily explored sex differences in PAH, augmenting our understanding to a much broader population encompassing all PH hemodynamic subtypes with potential implications for future sex-specific risk stratification and treatment in these groups.

Our findings regarding prevalence extend upon well-described sex differences in PAH, a subset of precapillary PH, where female sex has been established as a primary risk factor (3, 4). While prevalence of PAH is higher among women vs men, women with PAH demonstrate better RV function and overall clinical outcomes compared with men. A systematic review of 11 randomized trials found that women with PAH had lower right atrial pressures, higher cardiac index, and lower pulmonary vascular resistance compared with men (5). Similarly, a study by Kjellstrom et al examining sex differences in individuals with idiopathic PAH found that women were younger, had lower PVR, and fewer comorbidities than men (6). They found that although women were more prevalent in PAH, men had worse survival rates although this difference was attenuated by age. Our findings somewhat differ in clinical outcomes when examining a broader group of individuals with PH across hemodynamic subtypes, where risk of heart failure hospitalization but not mortality was significantly higher for men compared with women in all-comers with PH.

Conversely, our findings regarding the predominant male prevalence in post-capillary pulmonary hypertension is noteworthy. While our study is not able to attribute exact etiology, this is likely in the setting of left-sided heart disease, where known sex differences also exist. For example, prior studies have demonstrated that men are more likely to develop HF with reduced ejection fraction (HFrEF), while women are more predisposed to HF with preserved ejection fraction (HFpEF) (7, 8). While both HF subtypes have similarly wide ranges in estimated PH prevalence (40-75% for HFrEF, and 36-83% for HFpEF, (9–14) one study found that among individuals with HFpEF, 82% who develop PH are women, compared with 58% without (12). Our finding in prevalence of postcapillary PH is in keeping with the sex differences found in baseline prevalent HF amongst all individuals with PH, a co-morbidity present in 43% of men with PH but only 34% of women with PH (p-value < 0.001).

In prior studies of sex differences in RV function, women appear to have better RV systolic function compared with men both across community-based samples without PH and among those with PAH (15, 16). For example, in the Multi-Ethnic Study of Atherosclerosis, a large prospective study examining both men and women without clinical cardiovascular disease who underwent cardiac MRI, men had higher RV mass and volumes while women had higher RV function (15).

In PAH, RV function have also been demonstrated to be higher in women compared with men. In a small retrospective cohort study of 101 individuals with idiopathic PAH by Jacobs et al, sex differences in RV function were correlated with subsequent sex differences in response to treatment and survival (17). Although RV ejection fraction was found to be similar in both men and women at baseline, it declined in men and increased in women despite comparable reductions in pulmonary vascular resistance following initiation of treatment. Men also had significantly worse transplant-free survival compared with women; a mediation analysis found 39% of this survival difference was mediated through changes in RVEF for both women and men after initiating PAH medical therapies after adjusting for potential confounders.

Other types of PH have not been studied as extensively with respect to sex differences in RV function, although there is increasing interest in elucidating distinct phenotypes between men and women. In a retrospective study by Prins et al, male sex was the strongest predictor of RV dysfunction in group 3 PH, even after adjusting for pulmonary vascular resistance (18). Men with group 3 PH also showed a progressive decline in RV contractility with increasing pulmonary vascular resistance. Similarly, among individuals with heart failure with reduced ejection fraction (LVEF <35%), men were found nearly twice as likely have concomitant RV dysfunction compared with women despite similar LV ejection fraction (19). Among individuals with heart failure with preserved ejection fraction (HFpEF), men were found to have worse RV function compared with women at every mean pulmonary arterial pressure, with male sex again being an independent predictor of RV dysfunction (20). Our findings are in keeping with these prior studies, confirming a significant sex difference in RV dysfunction across all PH hemodynamic subtypes, with women demonstrating higher RV function compared with men in precapillary, postcapillary, and mixed PH.

The mechanisms underlying sex differences in RV dysfunction and PH remain unclear, although sex hormones are postulated to play an important role since cardiac myocytes express receptors for all major sex hormones (21). The “estrogen hypothesis” that higher estrogen levels confers a protective effect in pulmonary arterial pulmonary hypertension has been touted as a possible mechanism. This has been tested across various preclinical models: in a rat model of PH, estrogen E2 appears to promote adverse pulmonary vascular remodeling but also demonstrate RV protective effects in vivo through decreased RV apoptopic signaling, pro-inflammatory cytokine expression, oxidative stress, and mitochondrial dysfunction (22–25). Other studies have demonstrated a direct role of E2 on pulmonary vasculature, particularly increasing both proximal and distal pulmonary arterial compliance, which could have a downstream effect on RV remodeling and function (26–28). In humans, estrogen appears to favorably modulate RV function. In the MESA-Right Ventricle study which examined the role of sex hormones in individuals without clinical cardiovascular disease, Ventetuolo et al showed that post-menopausal women taking estradiol (an estrogen-based steroid hormone) for menopausal hormone therapy, had higher RV ejection fraction compared with men (29).

Our study has a number of limitations worth noting. First, RHC allowed for diagnosis and hemodynamic subtyping of PH but not clinical categorization by WHO classification, and definitive etiology of PH was not possible to ascertain comprehensively. Second, we examined individuals undergoing clinically indicated RHC, which may have resulted in selection bias, and generalizability of our study findings needs to be interpreted in that context. Additionally, due to the observational study design, we acknowledge the possibility of residual confounding, and causal inferences regarding sex differences cannot be drawn.

Our study also exhibits several strengths, most notably the large sample size and detailed hemodynamic data from right heart catheterizations in a broad population across all PH hemodynamic subtypes. One unique strength of our study is our use of hemodynamic indices of RV function rather than non-invasive assessment using echocardiography or MRI compared with prior studies. PAPi, RA:PCWP ratio, and RVSWI have all been correlated with clinical outcomes (30–34). Previous literature has also demonstrated PAPi may correlate more significantly to severe clinical RV failure in post-LVAD patients compared with echocardiographic-derived measurements, although this has not been as well-established in other clinical situations (35).

In sum, we found similar prevalence of overall PH among women and men, with women more likely to have precapillary PH while men were more likely to have postcapillary PH. Further, among individuals with PH, female sex was associated with better hemodynamic indices of RV function and lower risk of heart failure hospitalization.

These findings extend prior studies predominantly focused on sex differences in PAH to a large and clinically heterogeneous hospital-based sample with invasive hemodynamic assessment. Our findings illustrate the growing need for future studies to better understand underlying mechanisms and sex-specific considerations in RV dysfunction and associated clinical outcomes for individuals across all PH subtypes, as they may have important implications for risk stratification and management.

Sources of Funding

JEH is supported by NIH grants R01 HL134893, R01 HL140224, R01 HL160003, and K24 HL153669. ESL is supported by grants from the National Institutes of Health K23-HL159243 and the American Heart Association (853922).

Disclosures

None